FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4293574927> ?p ?o ?g. }

• W4293574927 endingPage "e30072" @default.
• W4293574927 startingPage "e30072" @default.
• W4293574927 abstract "Background: New hypoglycemic agents include sodium-glucose cotransporter-2 inhibitors (SGLT2is), glucagon-like peptide 1 receptor agonists (GLP1RAs), and dipeptidyl peptidase-4 inhibitors (DPP4is). The association between each class of these new hypoglycemic drugs and the risks of various digestive system diseases is unknown. We aimed to explore this relationship by performing a meta-analysis. Methods: We included large randomized trials of SGLT2is, GLP1RAs, and DPP4is. Outcomes of interest were 91 kinds of digestive diseases including 75 kinds of gastrointestinal disorders and 16 kinds of hepatobiliary disorders. Meta-analysis was done to generate pooled risk ratio (RR) and 95% confidence interval (CI). Subgroup analysis was conducted according to 3 different drug classes. Results: We included 21 large trials in this meta-analysis. Compared with placebo, GLP1RAs were associated with the higher risks of gastric ulcer hemorrhage (RR 2.68, 95% CI 1.07–6.68; P drug = .035; I 2 = 0), pancreatitis (RR 1.48, 95% CI 1.02–2.15; P drug = .041; I 2 = 0), cholangitis acute (RR 5.96, 95% CI 1.04–34.08; P drug = .045; I 2 = 0), and cholecystitis acute (RR 1.52, 95% CI 1.08–2.15; P drug = .017; I 2 = 1.5%), but were not significantly associated with the occurrences of the other 87 kinds of digestive diseases ( P drug ranged from .064 to .999). SGLT2is versus placebo were not significantly associated with the occurrences of 91 kinds of digestive diseases ( P drug ranged from .077 to .995). DPP4is versus placebo were not significantly associated with the occurrences of 91 kinds of digestive diseases ( P drug ranged from .085 to .999). Conclusions: Neither SGLT2is nor DPP4is are associated with the occurrences of various kinds of digestive diseases, whereas GLP1RAs are associated with the higher risks of 4 kinds of digestive diseases, namely, gastric ulcer hemorrhage, pancreatitis, cholangitis acute, and cholecystitis acute. These findings seem to suggest that GLP1RAs are not applicable for patients at high risk of 4 specific digestive diseases, whereas SGLT2is and DPP4is are safe for patients susceptible to digestive diseases. However, our findings require to be further verified by future studies with sufficient statistical power." @default.
• W4293574927 created "2022-08-30" @default.
• W4293574927 creator A5006006414 @default.
• W4293574927 creator A5053132919 @default.
• W4293574927 creator A5069216772 @default.
• W4293574927 date "2022-08-26" @default.
• W4293574927 modified "2023-10-14" @default.
• W4293574927 title "Meta-analysis of the association between new hypoglycemic agents and digestive diseases" @default.
• W4293574927 cites W2064130493 @default.
• W4293574927 cites W2098923148 @default.
• W4293574927 cites W2127854619 @default.
• W4293574927 cites W2142830692 @default.
• W4293574927 cites W2146264128 @default.
• W4293574927 cites W2282578582 @default.
• W4293574927 cites W2519510391 @default.
• W4293574927 cites W2572726339 @default.
• W4293574927 cites W2592954074 @default.
• W4293574927 cites W2626446274 @default.
• W4293574927 cites W2748536545 @default.
• W4293574927 cites W2752707491 @default.
• W4293574927 cites W2754041380 @default.
• W4293574927 cites W2754770935 @default.
• W4293574927 cites W2791740462 @default.
• W4293574927 cites W2805436655 @default.
• W4293574927 cites W2894746763 @default.
• W4293574927 cites W2899764361 @default.
• W4293574927 cites W2900149048 @default.
• W4293574927 cites W2900413769 @default.
• W4293574927 cites W2939222610 @default.
• W4293574927 cites W2948612418 @default.
• W4293574927 cites W2969385099 @default.
• W4293574927 cites W2971414122 @default.
• W4293574927 cites W2974260792 @default.
• W4293574927 cites W3006729360 @default.
• W4293574927 cites W3081830235 @default.
• W4293574927 cites W3086646659 @default.
• W4293574927 cites W3088173406 @default.
• W4293574927 cites W3089283105 @default.
• W4293574927 cites W3120876049 @default.
• W4293574927 cites W3130812076 @default.
• W4293574927 cites W3139300539 @default.
• W4293574927 cites W3174596488 @default.
• W4293574927 cites W4206445899 @default.
• W4293574927 doi "https://doi.org/10.1097/md.0000000000030072" @default.
• W4293574927 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36042668" @default.
• W4293574927 hasPublicationYear "2022" @default.
• W4293574927 type Work @default.
• W4293574927 citedByCount "2" @default.
• W4293574927 countsByYear W42935749272022 @default.
• W4293574927 countsByYear W42935749272023 @default.
• W4293574927 crossrefType "journal-article" @default.
• W4293574927 hasAuthorship W4293574927A5006006414 @default.
• W4293574927 hasAuthorship W4293574927A5053132919 @default.
• W4293574927 hasAuthorship W4293574927A5069216772 @default.
• W4293574927 hasBestOaLocation W42935749271 @default.
• W4293574927 hasConcept C126322002 @default.
• W4293574927 hasConcept C142724271 @default.
• W4293574927 hasConcept C187960798 @default.
• W4293574927 hasConcept C204787440 @default.
• W4293574927 hasConcept C27081682 @default.
• W4293574927 hasConcept C2776670229 @default.
• W4293574927 hasConcept C2780035454 @default.
• W4293574927 hasConcept C44249647 @default.
• W4293574927 hasConcept C71924100 @default.
• W4293574927 hasConcept C82789193 @default.
• W4293574927 hasConcept C90924648 @default.
• W4293574927 hasConcept C95190672 @default.
• W4293574927 hasConcept C98274493 @default.
• W4293574927 hasConceptScore W4293574927C126322002 @default.
• W4293574927 hasConceptScore W4293574927C142724271 @default.
• W4293574927 hasConceptScore W4293574927C187960798 @default.
• W4293574927 hasConceptScore W4293574927C204787440 @default.
• W4293574927 hasConceptScore W4293574927C27081682 @default.
• W4293574927 hasConceptScore W4293574927C2776670229 @default.
• W4293574927 hasConceptScore W4293574927C2780035454 @default.
• W4293574927 hasConceptScore W4293574927C44249647 @default.
• W4293574927 hasConceptScore W4293574927C71924100 @default.
• W4293574927 hasConceptScore W4293574927C82789193 @default.
• W4293574927 hasConceptScore W4293574927C90924648 @default.
• W4293574927 hasConceptScore W4293574927C95190672 @default.
• W4293574927 hasConceptScore W4293574927C98274493 @default.
• W4293574927 hasIssue "34" @default.
• W4293574927 hasLocation W42935749271 @default.
• W4293574927 hasLocation W42935749272 @default.
• W4293574927 hasLocation W42935749273 @default.
• W4293574927 hasLocation W42935749274 @default.
• W4293574927 hasOpenAccess W4293574927 @default.
• W4293574927 hasPrimaryLocation W42935749271 @default.
• W4293574927 hasRelatedWork W1539974851 @default.
• W4293574927 hasRelatedWork W2092961885 @default.
• W4293574927 hasRelatedWork W2340650675 @default.
• W4293574927 hasRelatedWork W2377377225 @default.
• W4293574927 hasRelatedWork W2396849083 @default.
• W4293574927 hasRelatedWork W2585787930 @default.
• W4293574927 hasRelatedWork W2602611201 @default.
• W4293574927 hasRelatedWork W2767082141 @default.
• W4293574927 hasRelatedWork W3194627231 @default.
• W4293574927 hasRelatedWork W4385186532 @default.

• next